Trends in non-metastatic prostate cancer management in the Northern and Yorkshire region of England, 2000-2006
Background: Our objective was to analyse variation in non-metastatic prostate cancer management in the Northern and Yorkshire region of England. Methods: We included 21 334 men aged ⩾55, diagnosed between 2000 and 2006. Principal treatment received was categorised into radical prostatectomy (11%), b...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2009-12, Vol.101 (11), p.1839-1845 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1845 |
|---|---|
| container_issue | 11 |
| container_start_page | 1839 |
| container_title | British journal of cancer |
| container_volume | 101 |
| creator | Fairley, L Baker, M Whiteway, J Cross, W Forman, D |
| description | Background:
Our objective was to analyse variation in non-metastatic prostate cancer management in the Northern and Yorkshire region of England.
Methods:
We included 21 334 men aged ⩾55, diagnosed between 2000 and 2006. Principal treatment received was categorised into radical prostatectomy (11%), brachytherapy (2%), external beam radiotherapy (16%), hormone therapy (42%) and no treatment (29%).
Results:
The odds ratio (OR) for receiving a radical prostatectomy was 1.53 in 2006 compared with 2000 (95% CI 1.26–1.86), whereas the OR for receiving hormone therapy was 0.57 (0.51–0.64). Age was strongly associated with treatment received; radical treatments were significantly less likely in men aged ⩾75 compared with men aged 55–64 years, whereas the odds of receiving hormone therapy or no treatment were significantly higher in the older age group. The OR for receiving radical prostatectomy, brachytherapy or external beam radiotherapy were all significantly lower in the most deprived areas when compared with the most affluent (0.64 (0.55–0.75), 0.32 (0.22–0.47) and 0.83 (0.74–0.94), respectively) whereas the OR for receiving hormone therapy was 1.56 (1.42–1.71).
Conclusions:
This study highlights the variation and inequalities that exist in the management of non-metastatic prostate cancer in the Northern and Yorkshire region of England. |
| doi_str_mv | 10.1038/sj.bjc.6605424 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2788251</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734151034</sourcerecordid><originalsourceid>FETCH-LOGICAL-c574t-89aae744b4109cdc44f9ee2d401a69e3c9c2a78aaabc4d631631b860948d70df3</originalsourceid><addsrcrecordid>eNp1kc2L1DAYxoMo7rh69aYEYfFiZ5M0bZqLIMv6AYte1oOn8DZ922mdJmPSCv73mzJ1VgUh5IPn937lIeQ5Z1vO8uoyDtt6sNuyZIUU8gHZ8CIXGa-Eekg2jDGVMS3YGXkS45CemlXqMTnjWjMpSrkh7jagayLtHXXeZSNOECeYeksPwS83pBacxUBHcNDhiG5a4GmH9LMP6QiOgmvoNx--x10fkAbseu-ob-m16_ZJe0NFKp2lrXxKHrWwj_hsPc_J1_fXt1cfs5svHz5dvbvJbKHklFUaAJWUteRM28ZK2WpE0UjGodSYW20FqAoAaiubMudp1VXJtKwaxZo2Pydvj3kPcz1iY1PXAfbmEPoRwi_joTd_K67fmc7_NEJVlSh4SvB6TRD8jxnjZMY-WtynedDP0ahc8iI5IBP56h9y8HNwaTojhNYVz0WRoO0RsulXY8D21ApnZjHSxMEkI81qZAp4-ecA9_jqXAIuVgCihX0bkkt9PHFCLMXVwl0euZgk12G4b--_pV8cIxxMc8BTyt_6HYFzwKY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229981325</pqid></control><display><type>article</type><title>Trends in non-metastatic prostate cancer management in the Northern and Yorkshire region of England, 2000-2006</title><source>MEDLINE</source><source>Nature</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Fairley, L ; Baker, M ; Whiteway, J ; Cross, W ; Forman, D</creator><creatorcontrib>Fairley, L ; Baker, M ; Whiteway, J ; Cross, W ; Forman, D</creatorcontrib><description>Background:
Our objective was to analyse variation in non-metastatic prostate cancer management in the Northern and Yorkshire region of England.
Methods:
We included 21 334 men aged ⩾55, diagnosed between 2000 and 2006. Principal treatment received was categorised into radical prostatectomy (11%), brachytherapy (2%), external beam radiotherapy (16%), hormone therapy (42%) and no treatment (29%).
Results:
The odds ratio (OR) for receiving a radical prostatectomy was 1.53 in 2006 compared with 2000 (95% CI 1.26–1.86), whereas the OR for receiving hormone therapy was 0.57 (0.51–0.64). Age was strongly associated with treatment received; radical treatments were significantly less likely in men aged ⩾75 compared with men aged 55–64 years, whereas the odds of receiving hormone therapy or no treatment were significantly higher in the older age group. The OR for receiving radical prostatectomy, brachytherapy or external beam radiotherapy were all significantly lower in the most deprived areas when compared with the most affluent (0.64 (0.55–0.75), 0.32 (0.22–0.47) and 0.83 (0.74–0.94), respectively) whereas the OR for receiving hormone therapy was 1.56 (1.42–1.71).
Conclusions:
This study highlights the variation and inequalities that exist in the management of non-metastatic prostate cancer in the Northern and Yorkshire region of England.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/sj.bjc.6605424</identifier><identifier>PMID: 19904264</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Aged ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Brachytherapy - trends ; Cancer Research ; Cancer therapies ; Clinical Study ; Drug Resistance ; Endocrine therapy ; England ; Epidemiology ; Humans ; Information services ; Male ; Medical research ; Medical sciences ; Metastasis ; Middle Aged ; Molecular Medicine ; Neoplasm Staging ; Nephrology. Urinary tract diseases ; Oncology ; Population ; Prostate cancer ; Prostatectomy - trends ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - radiotherapy ; Prostatic Neoplasms - surgery ; Prostatic Neoplasms - therapy ; Quality of life ; Radiation therapy ; Radiotherapy, Adjuvant - trends ; Registries ; Socioeconomic factors ; Surgery ; Surveillance ; Treatment Outcome ; Trends ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>British journal of cancer, 2009-12, Vol.101 (11), p.1839-1845</ispartof><rights>The Author(s) 2009</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Dec 1, 2009</rights><rights>Copyright © 2009 Cancer Research UK 2009 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c574t-89aae744b4109cdc44f9ee2d401a69e3c9c2a78aaabc4d631631b860948d70df3</citedby><cites>FETCH-LOGICAL-c574t-89aae744b4109cdc44f9ee2d401a69e3c9c2a78aaabc4d631631b860948d70df3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788251/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788251/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,2725,27922,27923,41486,42555,51317,53789,53791</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22229974$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19904264$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fairley, L</creatorcontrib><creatorcontrib>Baker, M</creatorcontrib><creatorcontrib>Whiteway, J</creatorcontrib><creatorcontrib>Cross, W</creatorcontrib><creatorcontrib>Forman, D</creatorcontrib><title>Trends in non-metastatic prostate cancer management in the Northern and Yorkshire region of England, 2000-2006</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Background:
Our objective was to analyse variation in non-metastatic prostate cancer management in the Northern and Yorkshire region of England.
Methods:
We included 21 334 men aged ⩾55, diagnosed between 2000 and 2006. Principal treatment received was categorised into radical prostatectomy (11%), brachytherapy (2%), external beam radiotherapy (16%), hormone therapy (42%) and no treatment (29%).
Results:
The odds ratio (OR) for receiving a radical prostatectomy was 1.53 in 2006 compared with 2000 (95% CI 1.26–1.86), whereas the OR for receiving hormone therapy was 0.57 (0.51–0.64). Age was strongly associated with treatment received; radical treatments were significantly less likely in men aged ⩾75 compared with men aged 55–64 years, whereas the odds of receiving hormone therapy or no treatment were significantly higher in the older age group. The OR for receiving radical prostatectomy, brachytherapy or external beam radiotherapy were all significantly lower in the most deprived areas when compared with the most affluent (0.64 (0.55–0.75), 0.32 (0.22–0.47) and 0.83 (0.74–0.94), respectively) whereas the OR for receiving hormone therapy was 1.56 (1.42–1.71).
Conclusions:
This study highlights the variation and inequalities that exist in the management of non-metastatic prostate cancer in the Northern and Yorkshire region of England.</description><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Brachytherapy - trends</subject><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Clinical Study</subject><subject>Drug Resistance</subject><subject>Endocrine therapy</subject><subject>England</subject><subject>Epidemiology</subject><subject>Humans</subject><subject>Information services</subject><subject>Male</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Neoplasm Staging</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Oncology</subject><subject>Population</subject><subject>Prostate cancer</subject><subject>Prostatectomy - trends</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Prostatic Neoplasms - therapy</subject><subject>Quality of life</subject><subject>Radiation therapy</subject><subject>Radiotherapy, Adjuvant - trends</subject><subject>Registries</subject><subject>Socioeconomic factors</subject><subject>Surgery</subject><subject>Surveillance</subject><subject>Treatment Outcome</subject><subject>Trends</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kc2L1DAYxoMo7rh69aYEYfFiZ5M0bZqLIMv6AYte1oOn8DZ922mdJmPSCv73mzJ1VgUh5IPn937lIeQ5Z1vO8uoyDtt6sNuyZIUU8gHZ8CIXGa-Eekg2jDGVMS3YGXkS45CemlXqMTnjWjMpSrkh7jagayLtHXXeZSNOECeYeksPwS83pBacxUBHcNDhiG5a4GmH9LMP6QiOgmvoNx--x10fkAbseu-ob-m16_ZJe0NFKp2lrXxKHrWwj_hsPc_J1_fXt1cfs5svHz5dvbvJbKHklFUaAJWUteRM28ZK2WpE0UjGodSYW20FqAoAaiubMudp1VXJtKwaxZo2Pydvj3kPcz1iY1PXAfbmEPoRwi_joTd_K67fmc7_NEJVlSh4SvB6TRD8jxnjZMY-WtynedDP0ahc8iI5IBP56h9y8HNwaTojhNYVz0WRoO0RsulXY8D21ApnZjHSxMEkI81qZAp4-ecA9_jqXAIuVgCihX0bkkt9PHFCLMXVwl0euZgk12G4b--_pV8cIxxMc8BTyt_6HYFzwKY</recordid><startdate>20091201</startdate><enddate>20091201</enddate><creator>Fairley, L</creator><creator>Baker, M</creator><creator>Whiteway, J</creator><creator>Cross, W</creator><creator>Forman, D</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20091201</creationdate><title>Trends in non-metastatic prostate cancer management in the Northern and Yorkshire region of England, 2000-2006</title><author>Fairley, L ; Baker, M ; Whiteway, J ; Cross, W ; Forman, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c574t-89aae744b4109cdc44f9ee2d401a69e3c9c2a78aaabc4d631631b860948d70df3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Brachytherapy - trends</topic><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Clinical Study</topic><topic>Drug Resistance</topic><topic>Endocrine therapy</topic><topic>England</topic><topic>Epidemiology</topic><topic>Humans</topic><topic>Information services</topic><topic>Male</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Neoplasm Staging</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Oncology</topic><topic>Population</topic><topic>Prostate cancer</topic><topic>Prostatectomy - trends</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Prostatic Neoplasms - therapy</topic><topic>Quality of life</topic><topic>Radiation therapy</topic><topic>Radiotherapy, Adjuvant - trends</topic><topic>Registries</topic><topic>Socioeconomic factors</topic><topic>Surgery</topic><topic>Surveillance</topic><topic>Treatment Outcome</topic><topic>Trends</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fairley, L</creatorcontrib><creatorcontrib>Baker, M</creatorcontrib><creatorcontrib>Whiteway, J</creatorcontrib><creatorcontrib>Cross, W</creatorcontrib><creatorcontrib>Forman, D</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fairley, L</au><au>Baker, M</au><au>Whiteway, J</au><au>Cross, W</au><au>Forman, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Trends in non-metastatic prostate cancer management in the Northern and Yorkshire region of England, 2000-2006</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2009-12-01</date><risdate>2009</risdate><volume>101</volume><issue>11</issue><spage>1839</spage><epage>1845</epage><pages>1839-1845</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Background:
Our objective was to analyse variation in non-metastatic prostate cancer management in the Northern and Yorkshire region of England.
Methods:
We included 21 334 men aged ⩾55, diagnosed between 2000 and 2006. Principal treatment received was categorised into radical prostatectomy (11%), brachytherapy (2%), external beam radiotherapy (16%), hormone therapy (42%) and no treatment (29%).
Results:
The odds ratio (OR) for receiving a radical prostatectomy was 1.53 in 2006 compared with 2000 (95% CI 1.26–1.86), whereas the OR for receiving hormone therapy was 0.57 (0.51–0.64). Age was strongly associated with treatment received; radical treatments were significantly less likely in men aged ⩾75 compared with men aged 55–64 years, whereas the odds of receiving hormone therapy or no treatment were significantly higher in the older age group. The OR for receiving radical prostatectomy, brachytherapy or external beam radiotherapy were all significantly lower in the most deprived areas when compared with the most affluent (0.64 (0.55–0.75), 0.32 (0.22–0.47) and 0.83 (0.74–0.94), respectively) whereas the OR for receiving hormone therapy was 1.56 (1.42–1.71).
Conclusions:
This study highlights the variation and inequalities that exist in the management of non-metastatic prostate cancer in the Northern and Yorkshire region of England.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>19904264</pmid><doi>10.1038/sj.bjc.6605424</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2009-12, Vol.101 (11), p.1839-1845 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2788251 |
| source | MEDLINE; Nature; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | Aged Biological and medical sciences Biomedical and Life Sciences Biomedicine Brachytherapy - trends Cancer Research Cancer therapies Clinical Study Drug Resistance Endocrine therapy England Epidemiology Humans Information services Male Medical research Medical sciences Metastasis Middle Aged Molecular Medicine Neoplasm Staging Nephrology. Urinary tract diseases Oncology Population Prostate cancer Prostatectomy - trends Prostatic Neoplasms - drug therapy Prostatic Neoplasms - radiotherapy Prostatic Neoplasms - surgery Prostatic Neoplasms - therapy Quality of life Radiation therapy Radiotherapy, Adjuvant - trends Registries Socioeconomic factors Surgery Surveillance Treatment Outcome Trends Tumors Tumors of the urinary system Urinary tract. Prostate gland |
| title | Trends in non-metastatic prostate cancer management in the Northern and Yorkshire region of England, 2000-2006 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T19%3A19%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Trends%20in%20non-metastatic%20prostate%20cancer%20management%20in%20the%20Northern%20and%20Yorkshire%20region%20of%20England,%202000-2006&rft.jtitle=British%20journal%20of%20cancer&rft.au=Fairley,%20L&rft.date=2009-12-01&rft.volume=101&rft.issue=11&rft.spage=1839&rft.epage=1845&rft.pages=1839-1845&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/sj.bjc.6605424&rft_dat=%3Cproquest_pubme%3E734151034%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=229981325&rft_id=info:pmid/19904264&rfr_iscdi=true |